Literature DB >> 10770730

Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America.

C A Kauffman1, R Hajjeh, S W Chapman.   

Abstract

UNLABELLED: The recommendations for the treatment of sporotrichosis were derived primarily from multicenter, nonrandomized treatment trials, small retrospective series, and case reports; no randomized, comparative treatment trials have been reported. Most cases of sporotrichosis are non life-threatening localized infections of the skin and subcutaneous tissues that can be treated with oral antifungal agents. The treatment of choice for fixed cutaneous or lymphocutaneous sporotrichosis is itraconazole for 36 months. The preferred treatment for osteoarticular sporotrichosis also is itraconazole, but therapy must be continued for at least 12 months. Pulmonary sporotrichosis responds poorly to treatment. Severe infection requires treatment with amphotericin B; mild to moderate infection can be treated with itraconazole. Meningeal and disseminated forms of sporotrichosis are rare and usually require treatment with amphotericin B. AIDS patients most often have disseminated infection and require life-long suppressive therapy with itraconazole after initial use of amphotericin B. OVERVIEW: Sporotrichosis is caused by the dimorphic fungus Sporothrix schenckii, which is found throughout the world in decaying vegetation, sphagnum moss, and soil. The usual mode of infection is by cutaneous inoculation of the organism. Pulmonary and disseminated forms of infection, although uncommon, can occur when S. schenckii conidia are inhaled. Infections are most often sporadic and usually associated with trauma during the course of outdoor work. Infection can also be related to zoonotic spread from infected cats or scratches from digging animals, such as armadillos. Outbreaks have been well-described and often are traced back to activities that involved contaminated sphagnum moss, hay, or wood. Most cases of sporotrichosis are localized to the skin and subcutaneous tissues. Dissemination to osteoarticular structures and viscera is uncommon and appears to occur more often in patients who have a history of alcohol abuse or immunosuppression, especially AIDS. Spontaneous resolution of sporotrichosis is rare, and treatment is required for most patients. Although sporotrichosis localized to skin and subcutaneous tissues is readily treated, management of osteoarticular, other localized visceral, and disseminated forms of sporotrichosis is difficult.
OBJECTIVE: The objective of these guidelines is to provide recommendations for the treatment of various forms of sporotrichosis. OUTCOMES: The desired outcomes of treatment include eradication of S. schenckii from tissues, resolution of symptoms and signs of active infection, and return of function of involved organs. In persons with AIDS, eradication of the organism may not be possible, but clinical resolution should be attained and subsequently maintained with suppressive antifungal therapy. EVIDENCE: The English-language literature on the treatment of sporotrichosis was reviewed. Although randomized, blinded, controlled treatment trials were sought, none were found to have been performed for the treatment of sporotrichosis. Therefore, most weight was placed on those reports that were derived from multicenter trials of specific treatment modalities for sporotrichosis. Small series from a single institution and individual case reports were accorded less importance. VALUES: The highest value was placed on clinical efficacy and the ability of the antifungal regimen to eradicate the organism, but safety, tolerability, and cost of therapy were also valued. BENEFITS AND COSTS: The benefits of successfully treating sporotrichosis accrue primarily for the patient. Because this infection is not spread from person-to-person, public health aspects of treatment are of minor importance. Most forms of sporotrichosis are not life-threatening; thus, therapy is aimed at decreasing morbidity, improving quality of life, and allowing the patient to return to occupational and familial pursuits. (ABSTRACT TRUNCATED)

Entities:  

Mesh:

Year:  2000        PMID: 10770730     DOI: 10.1086/313751

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine.

Authors:  Lidiane Meire Kohler; Paulo César Fialho Monteiro; Rosane Christine Hahn; Júnia Soares Hamdan
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

2.  In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia Dos Santos Lazéra; Bodo Wanke; Armando de Oliveira Schubach; Rodrigo de Almeida Paes; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 3.  Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literature.

Authors:  Simone Appenzeller; Tiago Nardi Amaral; Eliane Maria Ingrid Amstalden; Manoel Barros Bertolo; João Francisco Marques Neto; Adil Muhib Samara; Sandra Regina M Fernandes
Journal:  Clin Rheumatol       Date:  2005-12-07       Impact factor: 2.980

4.  Fixed sporotrichosis as a cause of a chronic ulcer on the knee.

Authors:  Rodrigo Roldán-Marín; José Contreras-Ruiz; Roberto Arenas; Elsa Vazquez-del-Mercado; Sonia Toussaint-Caire; María Elisa Vega-Memije
Journal:  Int Wound J       Date:  2009-02       Impact factor: 3.315

Review 5.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

6.  Delayed Diagnosis in a Case of Smoldering Sporotrichal Monoarthropathy.

Authors:  Rina Patel; Lindsay P Busby; Daria Motamedi
Journal:  J Radiol Case Rep       Date:  2019-01-31

Review 7.  Treatment of systemic fungal infections in older patients: achieving optimal outcomes.

Authors:  C A Kauffman; S A Hedderwick
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  Cutaneous sporotrichosis treated with photodynamic therapy: an in vitro and in vivo study.

Authors:  Yolanda Gilaberte; Carmen Aspiroz; M Carmen Alejandre; Elena Andres-Ciriano; Blanca Fortuño; Luis Charlez; Maria Jose Revillo; Michael R Hamblin; Antonio Rezusta
Journal:  Photomed Laser Surg       Date:  2013-12-13       Impact factor: 2.796

9.  An epidemic of sporotrichosis in Rio de Janeiro, Brazil: epidemiological aspects of a series of cases.

Authors:  M B L Barros; A O Schubach; T M P Schubach; B Wanke; S R Lambert-Passos
Journal:  Epidemiol Infect       Date:  2007-11-21       Impact factor: 2.451

10.  In vitro antifungal susceptibilities of five species of sporothrix.

Authors:  Rita Marimon; Carolina Serena; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.